Archive for the ‘RAS Blockade’ Category

August 20, 2009

Proteinuria: Is the ONTARGET renal substudy actually off target?

.   .   

ONTARGET showed that dual renin–angiotensin system blockade prevents microalbuminuria but facilitates transient renal function impairment in nonproteinuric patients with atherosclerotic vascular disease or diabetes. This articles suggests that these findings should not be used as an excuse not to optimize renin–angiotensin system inhibition and target urinary protein in patients with proteinuric nephropathies.

2 Comments Posted in Chronic Kidney Disease, RAS Blockade
July 10, 2009

Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?

.   .   

This paper reviews the available evidence regarding renoprotective effects of aliskiren, with an emphasis on comparison with ACE inhibitors and ARBs.

Comments Off on Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? Posted in RAS Blockade, Review
June 10, 2009

Effect of Telmisartan on Renal Outcomes: A Randomized Trial.

.   .   

This pre-specified subgroup analysis of the TRANSCEND study failed to show any significant benefit on renal outcomes between the intervention arm (using telmisartan) and placebo arm. This was not a study of chronic kidney disease patients, but rather examined patients with cardiovascular disease or diabetes, but without macroalbuminuria or heart failure.

Comments Off on Effect of Telmisartan on Renal Outcomes: A Randomized Trial. Posted in Chronic Kidney Disease, Hypertension, RAS Blockade
June 9, 2009

The hazards of dual renin-angiotensin blockade in chronic kidney disease.

.   .   

This paper reviews the pertinent literature that addresses dual RAS blockade in CKD and concludes that the simultaneous use of ACE inhibitors and ARBs should be discouraged in primary care.

Comments Off on The hazards of dual renin-angiotensin blockade in chronic kidney disease. Posted in Chronic Kidney Disease, RAS Blockade, Review
December 1, 2008

Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy?

.   .   

Comments Off on Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy? Posted in RAS Blockade
June 1, 2008

Aliskiren combined with losartan in type 2 diabetes and nephropathy.

.   .   

Comments Off on Aliskiren combined with losartan in type 2 diabetes and nephropathy. Posted in RAS Blockade
June 1, 2008

Aliskiren and dual therapy in type 2 diabetes mellitus.

.   .   

Comments Off on Aliskiren and dual therapy in type 2 diabetes mellitus. Posted in RAS Blockade
May 1, 2008

Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.

.   .   

Comments Off on Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. Posted in RAS Blockade
February 1, 2008

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.

.   .   

Comments Off on Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Posted in RAS Blockade
January 1, 2008

Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin Angiotensin System on Proteinuria in Renal Disease.

.   .   

Comments Off on Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin Angiotensin System on Proteinuria in Renal Disease. Posted in RAS Blockade
November 1, 2007

Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials.

.   .   

Comments Off on Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials. Posted in RAS Blockade
August 1, 2007

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

.   .   

Comments Off on Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Posted in RAS Blockade
June 1, 2007

Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency.

.   .   

Comments Off on Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency. Posted in RAS Blockade